TRANSVAC User Selection Panel

The TRANSVAC User selection panel is responsible for the selection of users for the transnational access services. It is composed of representatives of each access work package and five independent external experts.

The USP will use the report of the Scientific Advisory Committee on the peer-review of the applications as an aid in making their selection.

Clearly defined selection criteria will be used to prioritise the vaccines and include the following:

  • Progress of the vaccine towards clinical trials – impact of the testing on the clinical development process.
  • Importance of the vaccine – e.g. probability that the vaccine will improve quality of human life.
  • Relevance of the vaccine to the particular tests – likelihood that the data generated will be beneficial.

The selection of users will follow the principles of transparency, fairness and impartiality, and will take into account both the relevance and the scientific excellence of the proposals. Members of the TRANSVAC USP sign a confidentiality agreement containing provisions not less strict than those contained in this Consortium Agreement.


Dr James Robertson (Chair)

HPA National Institute for Biological Standards and Control

Dr James S Robertson is a Principal Scientist in Virology at the National Institute for Biological Standards and Control (NIBSC), a centre of the Health Protection Agency, UK.  He is a core member of the Vaccine Working Party (VWP) of the European Medicines Agency (EMA).  With a broad expertise in virology and molecular biology, he has contributed considerably to regulatory issues and the development of EU and WHO guidelines on pandemic influenza, many other vaccine issues and guidelines concerned with the viral safety of biologicals and biotechnology derived therapeutics.  His laboratory is dedicated to the research and development of influenza vaccines.

Dr Jan Langermans (Vice Chair)

Central Veterinary Institute, Wageningen UR

Jan A.M. Langermans, Ph.D., has been Chairman of the Animal Science Department, BPRC, Rijswijk, The Netherlands since 2008. His research interests include the development of animal models for infectious disease research, vaccine development, and immunology. Jan received his Ph.D. in 1992 in Leiden (with honours), and was Assistant Professor at LUMC in Leiden from 1992 to 1996. He headed the Parasitic and Bacterial Immunology Department at BPRC, Rijswijk from 1996-2003, covering malaria, TB and schistosoma research. Jan was Director of the Experimental Animal Services and BioMedical Research, ASG Wageningen UR, Lelystad  between 2003-2008.

Prof Dr Carlos Guzmán

Helmholtz Centre for Infection Research, Germany

Carlos GuzmanCarlos A. Guzmán Prof., MD, Ph.D. is the Head of the Department of Vaccinology and Applied Microbiology at the Helmholtz Centre for Infection Research (HZI; Braunschweig, Germany) and APL-Professor at the Medical School of Hannover. He is also external lecturer of the Doctorate in Biotechnology from the University of Catania (Italy) and Speaker for the Topic “Prevention & Therapy” within the “Infection Research” Program of the Helmholtz Association. He graduated in Medicine at the National University of Rosario and obtained his Board Certification in Medical Bacteriology in Argentina. Then, he moved to the Institute of Microbiology from the University of Genoa (Italy), as Research Fellow from the Italian Foreign Office Ministry. In Italy he also graduated as Doctor of Medicine and Surgery and obtained his Doctorate of Research in Microbiological Sciences. In 1994 he moved to Germany, where he became Head of the Vaccine Research Group at the German Research Centre for Biotechnology. In 2005 he was appointed as Head of the new HZI Department of Vaccinology. He has been working in the field of Vaccinology since 1989. His work has been instrumental for the development of new adjuvants and mucosal antigen delivery systems.

Dr Gwyn Davies

Independent business consultant

John Gwynfor Davies MA, DPhil (Oxon), works as an independent business consultant since 2005 and is Honorary Senior Lecturer at St. George’s University of London since 1995. He is also Board member of Wittycell SA, France since 2006 and Medipol SA, Switzerland since 2010.
He has extensive experience in industrial vaccine adjuvant research and development.
Previous position held are several posts leading to Head of R&D Projects and Partnerships, OM PHARMA, Switzerland 1991 – 2005, chairman of the European Adjuvant Advisory Committee (EAAC) 2007-2010 and academic research posts at Geneva and Oxford Universities.

Prof Martin Cranage

St George’s University of London

Martin Patrick Cranage, PhD, Professor, Hotung Chair of Molecular Vaccinology, Centre for Infection & Immunity, Clinical Sciences Division, St George’s University of London. His broad research interest is translational immunovirology with a specific focus on vaccine discovery for the prevention of mucosally acquired infection with HIV/SIV. Previous positions include scientific leader at the Centre for Applied Microbiology and Research, Salisbury UK, John Lucas Walker Senior Student in the Department of Pathology University of Cambridge and Research Associate in the Department of Virology, University of Newcastle upon Tyne.

Dr Mei Mei Ho

HPA National Institute for Biological Standards and Control

Mei Mei HoDr Mei Mei Ho is a Principal Scientist in the Bacteriology Division at the National Institute for Biological Standards and Control (NIBSC), a centre of the Health Protection Agency (HPA), UK. She has a broad experience in bacterial vaccines and leads a team focuses on R&D, quality control (ISO/IEC 17025 accredited) and standardisation of biological medicines used in tuberculosis, malaria and healthcare associated infections. She is a member of the Product Development Team in TB Vaccine Initiative and the World Health Organization (WHO) BCG working group, and provides regulatory advice on vaccine safety, quality and characterisation to vaccine developers and manufacturers.

Dr Nicolas Collin

University of Lausanne

Nicolas Collin is Head of the Vaccine Formulation Laboratory at University of Lausanne, Switzerland. The laboratory is a platform for global access to vaccine adjuvants and a training centre for vaccine formulation. Formerly, Dr Collin was technical officer at the World Health Organization (WHO), Geneva, and coordinator of the WHO vaccine task force during the pandemic influenza (H1N1) in 2009. Prior to this, he worked four years as project leader for the industry (Merial, Lyon) and completed a post-doctoral training at the National Institutes of Health (NIH) on Leishmania vaccines. Nicolas Collin is Doctor in Veterinary Medicine (National Veterinary School of Toulouse) and holds a PhD in Molecular Virology (University of Toulouse III).

Prof Michel Klein, MD

VaxiBio Inc.

Chairman of VaxiBio Inc., Canada, he graduated from the Institut Pasteur in immunology. He held the positions of VP Research of Pasteur Mérieux Connaught then of VP, Science and Technology, of Aventis-Pasteur. He was Professor of Immunology at the University of Toronto for 25 years. He served on the EDCTP Advisory Board of the EU. He is a permanent visiting professor with NHRI, Taiwan. He is the author of more than 200 scientific publications and 350 patents in the fields of vaccinology, immunology, infectious diseases and biotechnology. He serves on several Boards of Directors and Scientific Advisory Boards. He is a knight in the French order of the Légion d’Honneur.

Dr Roger LeGrand

Commissariat à l'Energie Atomique

Dr Roger Le Grand has been heading the Immuno-Virology Division at the Institute of Emerging Diseases and Innovative Therapies at the Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), France, since 2007. Dr. Le Grand has worked as an expert providing consulting services to several French national research agencies, the French government, the Bill and Melinda Gates Foundation, as well as the WHO. His research interests previously focused on non human primate models of human viral infections for study host/pathogen interactions and prevention of virus transmission. Nowadays, Dr. Le Grand’s research group is developing NHP models for HIV, HBV, Dengue, Yellow Fever and Chikungunya. He is particularly interested in analyzing the molecular and cellular mechanisms that play a role in chronic viral infections as well as emerging viral infections.